Trial Profile
A Prospective study of gas-assisted vitreomacular adhesion (VMA) release combined with intravitreal Ranibizumab in patients with exudative age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Apr 2017
Price :
$35
*
At a glance
- Drugs Perflutren (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 17 Apr 2017 New trial record